Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Erasca Inc ERAS

Healthcare Biotechnology
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also... see more

Current News (NDAQ:ERAS)

Erasca to Present at Upcoming Conferences in February

GlobeNewswire 11 days ago

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire January 23, 2026

Erasca Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire January 21, 2026

Erasca Announces Proposed Public Offering of $150 Million of Common Stock

GlobeNewswire January 20, 2026

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

GlobeNewswire January 12, 2026

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

Erasca to Present at the 8th Annual Evercore Healthcare Conference

GlobeNewswire November 25, 2025

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

GlobeNewswire November 12, 2025

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

GlobeNewswire November 6, 2025
View More News ››

Opinion & Analysis (NDAQ:ERAS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ERAS)

Be the first to post on this bullboard.

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic ...
View More »

Podcasts